Clinical trials: Newly Diagnosed Multiple Myeloma
Newly Diagnosed Multiple Myeloma
To Evaluate Safety and Efficacy of Anitocabtagene Autoleucel Versus Autologous Stem Cell Transplant in Newly Diagnosed Multiple Myeloma
The goal of this clinical study iMMagine-6 is to compare and assess the safety and effectiveness of anitocabtagene autoleucel versus autologous stem cell transplant in participants with newly diagnosed multiple myeloma (NDMM).
- Trial name
- iMMagine-6 (NCT07903506)
- Testing
- Anitocabtagene Autoleucel, Isatuximab, Bortezomib
- Volunteers
- 750 people
- Sponsor
- Kite, A Gilead Company
Newly Diagnosed, Multiple Myeloma
Comparison of Melphalan-Prednisone (MP) to MP Plus Thalidomide in the Treatment of Newly Diagnosed Very Elderly Patients (> 75 Years) With Multiple Myeloma
In multiple myeloma, combination chemotherapy with melphalan plus prednisone has been usedsince the 1960s and is regarded as the standard of care in very elderly patients.
- Trial name
- IFM 01/01 (NCT00644306)
- Testing
- Thalidomide, melphalan, prednisone, melphalan, prednisone, thalidomide
- Where
- France
- Volunteers
- 232 people
- Sponsor
- Central Hospital, Nancy, France
Multiple Myeloma, Daratumumab
Daratumumab-containing Induction Effects on Stem Cells Mobilization, colLection and Engraftment in Newly Diagnosed Multiple MyelomA Patients.
Daratumumab is a human first-in-class monoclonal antibody that targets a cluster of differentiation (CD) 38, a cell surface protein that is overexpressed on multiple myeloma (MM) cells, showing significant activity in…
- Conditions
- Multiple Myeloma, Daratumumab, Autologous Stem Cell Transplantation, Leukapheresis
- Trial name
- DILEMMA (NCT05835726)
- Testing
- Daratumumab
- Where
- Italy
- Volunteers
- 188 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Multiple Myeloma
IMMUNOPLANT for Newly Diagnosed Multiple Myeloma
The purpose of this study is to determine whether Linvoseltamab therapy in patients with newly diagnosed multiple myeloma will convert the disease status from minimal residual disease (MRD)-positive to MRD-negative, and increase…
- Trial name
- IMMUNOPLANT (NCT06376526)
- Testing
- Linvoseltamab
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- Dickran Kazandjian, MD
Multiple Myeloma
Combination Study of Revlimid®, Velcade® Dexamethasone and Doxil® (RVDD)for Newly Diagnosed Multiple Myeloma
This research study is evaluating an investigational combination of four drugs called Revlimid® (lenalidomide), Velcade® (bortezomib), Dexamethasone and Doxil® (RVDD) as a possible treatment for newly diagnosed multiple myeloma.
- Trial name
- RVDD (NCT00724568)
- Testing
- Lenalidomide, Bortezomib, Dexamethasone
- Where
- 6 sites in United States, Canada
- Volunteers
- 74 people
- Sponsor
- University of Michigan Rogel Cancer Center
Multiple Myeloma
THAL-DEX Incorporated Into Double PBSC Autotransplantation for Untreated Multiple Myeloma (MM)
The marked activity of thalidomide (thal) and dexamethasone (dex) in relapsed and refractory multiple myeloma (MM) provided the basis for this phase 2 clinical study aimed at investigating the efficacy and toxicity of thal-dex…
- Trial name
- NCT01341262
- Testing
- Thalidomide, Dexamethasone, Zoledronic acid
- Volunteers
- 378 people
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
Multiple Myeloma
Phase II Study of Thalidomide, Clarithromycin, Lenalidomide, and Dexamethasone for Newly Diagnosed Multiple Myeloma
Study Objectives 1. Evaluate the efficacy of the combination of thalidomide (Thalomid®), clarithromycin (Biaxin®), lenalidomide (Revlimid®), and dexamethasone (Decadron®) as an induction therapy for patients with newly diagnosed…
- Trial name
- T-BiRD (NCT00538733)
- Testing
- thalomid, lenalidomide, clarithromycin
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Weill Medical College of Cornell University
Multiple Myeloma
Study of Thrombin Generation During the 3 First Cycles of Chemotherapy in Patients With Newly Diagnosed Multiple Myeloma
Patients with Multiple Myeloma (MM) are at increased risk of venous thromboembolic event, especially in newly diagnosed patients and during induction treatment with thalidomide in combination with dexamethasone.
- Trial name
- METRO (NCT01508416)
- Where
- 5 sites in France
- Volunteers
- 71 people
- Sponsor
- Centre Hospitalier Universitaire de Saint Etienne
Previously Untreated Symptomatic Multiple Myeloma
Lenalidomide, Adriamycin, Dexamethasone (RAD) Versus Lenalidomide, Bortezomib, Dexamethasone (VRD) for Induction in Newly Diagnosed Multiple Myeloma Followed by Response-adapted Consolidation and Lenalidomide Maintenance
The investigators propose this study utilizing Lenalidomide, Adriamycin, Dexamethasone (RAD) as comparator arm for Lenalidomide, Bortezomib, Dexamethasone (VRD) with the latter being considered a novel "standard" as an induction…
- Trial name
- NCT01685814
- Testing
- Lenalidomide, Bortezomib, autologous stem cell transplant, allogeneic stem cell transplant
- Where
- 32 sites in Germany
- Volunteers
- 406 people
- Sponsor
- Wuerzburg University Hospital
Stage I Multiple Myeloma, Stage II Multiple Myeloma
Carfilzomib, Lenalidomide, and Dexamethasone Before and After Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma
This phase II trial studies how well carfilzomib, lenalidomide, and dexamethasone before and after stem cell transplant works in treating patients with newly diagnosed multiple myeloma.
- Conditions
- Stage I Multiple Myeloma, Stage II Multiple Myeloma, Stage III Multiple Myeloma
- Trial name
- NCT01816971
- Testing
- dexamethasone, carfilzomib, lenalidomide
- Where
- 5 sites in United States, Canada
- Volunteers
- 76 people
- Sponsor
- University of Chicago
Exercise Behavior, Multiple Myeloma
Exercise Phenotyping Prior to Chemotherapy in Newly Diagnosed Multiple Myeloma (MM-Exercise)
MM-Exercise is a prospective, single-centre, observational pilot study of patients with newly diagnosed multiple myeloma who have not yet started chemotherapy and whose resting echocardiogram is unremarkable or only mildly…
- Trial name
- MM-Exercise (NCT07851493)
- Where
- Germany
- Volunteers
- 80 people
- Sponsor
- Technical University of Munich
Multiple Myeloma
Study of Teclistamab in Combination in Elderly Patients With Multiple Myeloma
The primary hypothesis of this study is that teclistamab SC in combination with daratumumab SC or lenalidomide will be safe and induce a high rate of VGPR or better in newly diagnosed multiple myeloma patients This is an…
- Trial name
- IFM2021-01 (NCT05572229)
- Testing
- Teclistamab, Daratumumab, Lenalidomide
- Where
- 22 sites in France
- Volunteers
- 74 people
- Sponsor
- University Hospital, Lille
Multiple Myeloma
UARK 98-026 TT II: Multiple Myeloma Evaluating Anti-Angiogenesis With Thalidomide and Post-Transplant Consolidation Chemotherapy
This study has been designed to evaluate whether "anti-angiogenesis" therapy with thalidomide and whether additional chemotherapy after transplant will be beneficial.
- Trial name
- NCT00083551
- Testing
- Thalidomide, Ara-C, BCNU
- Where
- United States
- Volunteers
- 668 people
- Sponsor
- University of Arkansas
DS Stage I Plasma Cell Myeloma, DS Stage II Plasma Cell Myeloma
S1211 Bortezomib, Dexamethasone, and Lenalidomide With or Without Elotuzumab in Treating Patients With Newly Diagnosed High-Risk Multiple Myeloma
This partially randomized phase I/II trial studies the side effects and best dose of elotuzumab and to see how well it works when given together with lenalidomide, bortezomib, and dexamethasone in treating patients with newly…
- Conditions
- DS Stage I Plasma Cell Myeloma, DS Stage II Plasma Cell Myeloma, DS Stage III Plasma Cell Myeloma
- Trial name
- NCT01668719
- Testing
- Bortezomib, Dexamethasone, Elotuzumab
- Where
- 417 sites in United States
- Volunteers
- 142 people
- Sponsor
- SWOG Cancer Research Network
Multiple Myeloma
Ixazomib, Lenalidomide, and Combination for Maintenance in NDMM Patients
The purpose of this study is to evaluate the real-world efficacy and safety of ixazomib, lenalidomide, or ixazomib in combination with lenalidomide as maintenance therapy in patients with newly diagnosed multiple myeloma in China.
- Trial name
- NCT04217967
- Testing
- Ixazomib, Lenalidomide
- Where
- China
- Volunteers
- 211 people
- Sponsor
- Peking Union Medical College Hospital
Hematological Patients, Newly Diagnosed Multiple Myeloma
Biomarkers in Multiple Myeloma
The association between multiple myeloma (MM) and venous thromboembolism (VTE) is well known. Indeed, the incidence of VTE is increased in patients with newly diagnosed MM and in patients treated by immunomodulatory drugs in…
- Conditions
- Hematological Patients, Newly Diagnosed Multiple Myeloma, Chemotherapy
- Trial name
- VESICOM (NCT05259553)
- Testing
- Blood samples
- Where
- 2 sites in France
- Volunteers
- 70 people
- Sponsor
- Centre Hospitalier Universitaire de Saint Etienne
Multiple Myeloma
Bortezomib (Velcade®), Lenalidomide (Revlimid®) and IV Busulfan (Busilvex®) in Patients Under 65 Years Old
This protocol is a national, multicenter, comparative, open-label, randomized trial comparing the progression free survival (PFS) of two pre-transplant conditioning regimens (BUMEL versus. MEL-200).
- Trial name
- GEM2012MENOS65 (NCT01916252)
- Testing
- bortezomib (Velcade ®), lenalidomide (Revlimid®), busulfan (Busilvex ®)
- Where
- 74 sites in Spain
- Volunteers
- 460 people
- Sponsor
- PETHEMA Foundation
Multiple Myeloma
Melphalan, Prednisone, and CC-5013 (Revlimid) as Induction Therapy in Multiple Myeloma
The purpose of this study is to evaluate the safety and efficacy of the association of Melphalan/Prednisone/Revlimid (MPR) as induction treatment for newly diagnosed myeloma patients over age 65 or those under 65 years who refuse…
- Trial name
- NCT00396045
- Testing
- Revlimid (CC-5013)
- Where
- 9 sites in Italy
- Volunteers
- 54 people
- Sponsor
- University of Turin, Italy
Multiple Myeloma, Myeloma
Multicenter Open Label Phase 3 Study of Isatuximab Plus Lenalidomide and Dexamethasone With/Without Bortezomib in the Treatment of Newly Diagnosed Non Frail Transplant Ineligible Multiple Myeloma Elderly Patients (≥ 65; < 80 Years).
Overall the issue of patients above 65-70 years of age being that it is impossible for most of them to undergo an intensive treatment like autologous stem cell transplant with little prospect of debulking effectively the bone…
- Trial name
- NCT04751877
- Testing
- Isatuximab, Lenalidomide, Bortezomib
- Where
- France
- Volunteers
- 270 people
- Sponsor
- Poitiers University Hospital
Multiple Myeloma
Study of BiRd Regimen Combined With BCMA CAR T-cell Therapy in Newly Diagnosed Multiple Myeloma (MM) Patients
The purpose of this study is to evaluate the safety and efficacy of BiRd regimen combined with BCMA CAR T cell therapy in newly diagnosed multiple myeloma patients
- Trial name
- NCT04287660
- Testing
- clarithromycin, lenalidomide, dexamethasone and autologous BCMA-directed CAR T-cells
- Where
- China
- Volunteers
- 20 people
- Sponsor
- The First Affiliated Hospital of Soochow University